IFNG and neoplasm: Anti-PD-1/PD-L1 therapies, also known as immune checkpoint inhibitors, aim to block this interaction, thereby revitalizing T cell activity and restoring anti-tumor immunity.212–214 Despite their potential, due to various immune escape mechanisms employed by cancer cells, these treatments are effective in only about 20% of cancer patients.215–217 A recent study has revealed a pivotal role of YAP nuclear phase separation in the adaptive resistance to tumor immunotherapy driven by IFN-γ.